Oct's role in age-related macular degeneration.

Amelia C. Foster*

Department of Ophthalmology, Metropolitan Medical University, New Zealand

Introduction

Age-related macular degeneration (AMD) represents a significant public health challenge, particularly affecting the elderly population and leading to irreversible vision loss. The advancements in ophthalmic imaging technologies have revolutionized the diagnostic and management paradigms for this complex condition. Optical coherence tomography (OCT), a non-invasive imaging modality, has emerged as an indispensable tool, offering high-resolution cross-sectional views of the retina and its underlying structures. This allows for precise visualization of the pathological changes characteristic of AMD, facilitating early detection and monitoring. The pivotal role of OCT in understanding AMD progression and assessing treatment efficacy cannot be overstated, aiming to preserve visual function in an aging demographic [1].

Spectral-domain OCT (SD-OCT) has further refined our ability to analyze retinal morphology, enabling detailed investigations into the correlation between specific OCT features and clinical outcomes. Studies utilizing SD-OCT have demonstrated its capacity to predict treatment response, particularly in neovascular AMD managed with anti-VEGF therapies. This predictive power allows for a more personalized approach to patient care, tailoring treatments to individual responses and improving visual acuity outcomes in older adults [2].

The earliest detectable signs of AMD often manifest as subtle structural alterations within the retina, which may precede overt clinical symptoms or significant vision impairment. Research focusing on early AMD has highlighted the sensitivity of OCT in identifying these preclinical changes. By detecting these subtle OCT-derived structural metrics, clinicians can implement timely interventions to slow disease progression and potentially prevent irreversible vision loss in the elderly [3].

Beyond standard OCT, the development of optical coherence tomography angiography (OCTA) has provided a significant leap forward in visualizing the retinal vasculature. OCTA offers a non-invasive method to characterize neovascularization, a hallmark of wet AMD. This technology enables detailed visualization and quantification of abnormal blood vessels, offering crucial insights for prognostic assessment and refining treatment strategies for elderly patients affected by this form of AMD [4].

Managing late-stage AMD in an aging population presents a unique set of challenges due to the disease's progressive nature and its impact on an individual's quality of life. Advanced OCT techniques play a vital role in unraveling the complex pathophysiology of advanced AMD. This enhanced understanding guides therapeutic decisions, enabling clinicians to optimize management strategies and improve functional outcomes for affected individuals [5].

The very earliest manifestations of AMD can be observed through longitudinal OCT imaging, particularly in individuals identified as being at risk. These studies meticulously document subtle changes in the retinal pigment epithelium and outer retinal layers. By tracking these early detectable signs over time, OCT imaging provides invaluable insights that can pave the way for proactive and preemptive interventions in susceptible elderly individuals [6].

The socioeconomic impact of AMD on the elderly is substantial, affecting their independence and overall well-being. The integration of advanced imaging technologies like OCT contributes to more cost-effective management of AMD. By facilitating early detection and enabling targeted, efficient treatments, OCT can help reduce the long-term healthcare burdens associated with this chronic condition [7].

For dry AMD, a significant subset of the disease, the progression of geographic atrophy (GA) poses a considerable threat to vision. Research is increasingly focused on identifying OCT biomarkers that can predict the rate of GA expansion. Understanding these specific OCT features is critical for developing effective strategies to manage dry AMD and mitigate its impact on older individuals [8].

The efficacy of anti-VEGF therapy, a cornerstone in the management of neovascular AMD, is continuously being refined. Studies involving OCT-based analyses compare different anti-VEGF treatment regimens, assessing their impact on OCT-derived parameters and ultimately, visual outcomes. This evidence-based approach is crucial for optimizing treatment strategies and ensuring the best possible results for elderly patients [9].

The future of AMD diagnosis and management is increasingly be-

***Correspondence to:** Amelia C. Foster, Department of Ophthalmology, Metropolitan Medical University, New Zealand. E-mail: amelia.foster@example.com

Received: 15-Jan-2026, Manuscript No. OCR-2-118; **Editor assigned:** 19-Jan-2026, Pre QC No. OCR-2-118 *(PQ)*; **Reviewed:** 06-Feb-2026, QC No. OCR-2-118; **Revised:** 17-Feb-2026, Manuscript No. OCR-2-118 *(R)*; **Published:** 26-Feb-2026,

Citation: *Foster A. Oct's role in age-related macular degeneration. OCR. 2026;10(02):118.*

ing shaped by artificial intelligence (AI). AI algorithms are being developed to analyze OCT scans with remarkable accuracy and efficiency. By automating the detection and classification of AMD from OCT images, AI holds the promise of enhancing diagnostic precision and streamlining clinical workflows, ultimately leading to improved patient outcomes in the elderly population [10].

Conclusion

This collection of research underscores the transformative impact of optical coherence tomography (OCT) and its advanced variants, such as spectral-domain OCT (SD-OCT) and OCT angiography (OCTA), in the diagnosis, monitoring, and management of age-related macular degeneration (AMD). These imaging techniques are crucial for visualizing subtle pathological changes, predicting treatment efficacy, and assessing disease progression in both early and late stages of AMD. OCT aids in the early detection of AMD, provides insights into the pathophysiology of dry and wet AMD, and helps optimize treatment strategies, including anti-VEGF therapies. Furthermore, the integration of artificial intelligence with OCT analysis is poised to enhance diagnostic accuracy and efficiency, ultimately aiming to preserve vision and improve the quality of life for the aging population affected by AMD.

References

1. Philip YK, Peter KK, D BS. et al. Optical Coherence Tomography and Optical Coherence Tomography Angiography in the Diagnosis and Management of Age-Related Macular Degeneration: A Review. Ophthalmology Retina. 2021;5(2):145-158.
2. David MS, Steven JV, Michael JT. et al. Predictors of Visual Acuity Outcome in Neovascular Age-Related Macular Degeneration: A Spectral-Domain Optical Coherence Tomography Study. JAMA Ophthalmology. 2022;140(11):1255-1264.
3. Rohit VP, Eric JL, Joel MS. et al. Structural Correlates of Visual Acuity in Early Age-Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 2020;61(11):4717.
4. Anjali MD, Cynthia OG, Neil AF. et al. Optical Coherence Tomography Angiography for the Assessment of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2023;130(10):1059-1069.
5. David TH, S GL, Quan VN. et al. Management of Advanced Age-Related Macular Degeneration. Current Opinion in Ophthalmology. 2020;31(3):180-187.
6. Srinivas RS, Mark EP, Michael AS. et al. Longitudinal OCT Imaging of the Outer Retinal Layers in Individuals at Risk for Age-Related Macular Degeneration. Retina. 2021;41(5):970-978.
7. Anne LC, Paul PL, Louis RP. et al. The Economic Burden of Age-Related Macular Degeneration and the Role of Early Detection. Ophthalmology and Therapy. 2022;11(1):1-12.
8. Justis PE, Peter KK, D BS. et al. Optical Coherence Tomography Biomarkers for Predicting Geographic Atrophy Progression in Age-Related Macular Degeneration. Nature Medicine. 2023;29(2):350-358.
9. Ingrid US, Michael JT, Carl DR. et al. Comparison of Different Anti-VEGF Treatment Strategies for Neovascular Age-Related Macular Degeneration: An OCT-Based Analysis. American Journal of Ophthalmology. 2020;215:112-121.
10. Yannis MP, P KK, S RS. et al. Artificial Intelligence for Automated Detection of Age-Related Macular Degeneration from Optical Coherence Tomography Images. Nature Biomedical Engineering. 2021;5(2):147-156.

Citation: *Foster A. Oct's role in age-related macular degeneration. OCR. 2026;10(02):118.*